Skip to main content

Abstract

To understand the potential role of cyclooxygenase (COX) in normal and inflammatory human diseases, we characterized the expression of COX-1 and COX-2 in biopsies of osteoarthritis, atherosclerosis, and cancer. Tissues were prepared for immunohistochemistry by standard methods, and representative cases assayed via Western blot and quantitative RT-PCR. COX-2 was not detected in normal human tissues with few exceptions. Moderate to marked COX-2 was observed in the macula densa (MD) and thick ascending limb (TAL) in human fetal kidneys, but was not detected in neonatal and adult MD and TALs. Low level, constitutive COX-2 was detected in colonic epithelium, peribronchial glands, and pancreatic ductal epithelium. Low to moderate COX-2 was detected basally in the cortex, hippocampus, hypothalamus, and spinal cord, and in reproductive tissues during ovulation, implantation and labor. No COX-2 was detected in the existing vasculature in normal tissues, and was also not expressed throughout the ductus arteriosus. COX-2 was markedly induced in human tissues of osteoarthritis, atherosclerosis and cancer. COX-2 was prominently expressed in the synovium, fibrocartilage of osteophytes, and in the blood vessels in the osteoarthritic (OA) knee joint. COX-2 was also prominently detected in the macrophages/ foam cells in atherosclerotic plaques, and in the endothelium overlying and immediately adjacent to the fibrofatty lesion. Moderate-to intense COX-2 expression was consistently observed in the inflammatory cells, neoplastic lesions, and blood vessels in all epithelial-derived human cancers studied. In contrast, COX-1 was relatively ubiquitously observed in both normal and pathophysiological conditions. These data collectively imply COX-2 plays an important role in mediating a variety of inflammatory diseases, and imply COX-2 inhibitors may be effective in the prevention and/or treatment of OA, heart disease, and epithelial cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. G.N. Levy, Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer, FASEB J. 11:234 (1997).

    CAS  PubMed  Google Scholar 

  2. H.R. Herschman, Prostaglandin synthase-2, Biochem. Biophys. Acta. 1299:125 (1996).

    Google Scholar 

  3. K. Seibert, Y. Zhang, K. Leahy et al., Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain, Proc. Natl. Acad. Sci. USA 91:12013 (1994).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. R.N. DuBoise, R.S. Abramson, L. Crofford, R.A. Gupta, L.S. Simon et al., Cyclooxygenase in biology and disease, FASEB J. 12:1063 (1998).

    Google Scholar 

  5. M. Oshima, J.E. Dinchuck, S.L. Kargman, H. Oshima, B. Hancock, et al., Suppression of intestinal polyposis in APC delta 16 knockout mice by inhibition of cyclooxygenase-2 (COX-2), Cell 87:803 (1996).

    Article  CAS  PubMed  Google Scholar 

  6. C.C. Chan, S. Boyce, C. Brideau et al., Rofecoxib [Vioxx, MK-0966; 4-(4’-methylsulfonylphenyl)-3phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles, J. Pharmacol. Exp. Ther. 290:551 (1999).

    CAS  PubMed  Google Scholar 

  7. L.S. Simon, F.L. Lanza, P.E. Lipsky et al., Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects, Arthritis Rheum. 41(9):1591 (1998).

    Article  CAS  PubMed  Google Scholar 

  8. A.T. Koki, K.M. Leahy, and J.L. Masferrer, Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy, Exp. Opin. Invest. Drugs 8(10):1623 (1999).

    Article  CAS  Google Scholar 

  9. Renal paper

    Google Scholar 

  10. J.L. Masferrer, P.C. Isakson, and K. Seibert, Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agent that spare the gastrointestinal tract, Gastroeneterol. Clin. North Am. 25:363 (1996).

    CAS  Google Scholar 

  11. L.J. Marnett, Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer, Preventive Med. 24:103 (1995).

    Article  CAS  Google Scholar 

  12. M.J. Reeves, P.A. Newcomb, A. Trentham-Dietz, B.E. Storer, and P.L. Remington, Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women, Cancer Epid. Biomark. Prey. 5:955 (1996).

    CAS  Google Scholar 

  13. M.J. Thun, M.M. Namboodiri, E.E. Calle, W.D. Flanders, and C.W. Heath, Aspirin use and risk of fatal cancer, Cancer Res. 53:1322 (1993).

    CAS  PubMed  Google Scholar 

  14. R.E. Harris, K.K. Namboodiri, and W.B. Farrar, Nonsteroidal antiinflammatory drugs and breast cancer, Epidemiol. 5:138 (1996).

    Google Scholar 

  15. D.M. Schreinemachers, and R.B. Everson, Aspirin use and lung, colon, and breast cancer incidence in a prospective study, Epidemiol. 5:138 (1994).

    Article  CAS  Google Scholar 

  16. D.C. Farrow, T.L. Vaughan, P.D. Hansten et al., Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer, Cancer Epid. Biom. & Prey. 7:97 (1998).

    CAS  Google Scholar 

  17. B.S. Reddy, Y. Hirose, R. Lubet, V. Steele, G. Kelloff, S. Paulson, K, Seibert, and C.V. Rao, Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis, Cancer Res. 60(2):293 (2000).

    CAS  PubMed  Google Scholar 

  18. T. Kawamori, C.V. Rao, K. Seibert, and B.S. Reddy, Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis, Cancer Res. 58:409 (1998).

    CAS  PubMed  Google Scholar 

  19. S.M. Fischer, H.H. Lo, G.B. Gordon et al., Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis, Molec. Carcinogenesis 25:231 (1999).

    Article  CAS  Google Scholar 

  20. J.L. Masferrer, K.M. Leahy, A.T. Koki et al., Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors, Cancer Res. (in press).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Koki, A. et al. (2002). Cyclooxygenase-2 In Human Pathological Disease. In: Honn, K.V., Marnett, L.J., Nigam, S., Dennis, E., Serhan, C. (eds) Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury, 5. Advances in Experimental Medicine and Biology, vol 507. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0193-0_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0193-0_28

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-4960-0

  • Online ISBN: 978-1-4615-0193-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics